# Beijing Biotech clinical trials: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Beijing Biotech as lead sponsor, 32 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Beijing Biotech: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/beijing-biotech

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 4, 2026 | NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744256) |
| June 11, 2026 | NCT07641049 | Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | Beijing Biotech | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641049) |
| June 11, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Biliary... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641036) |
| June 11, 2026 | NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Beijing Biotech | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, Advanced/Metastatic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641023) |
| June 4, 2026 | NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627711) |
| June 4, 2026 | NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Beijing Biotech | Phase 1/2 | Recruiting | Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627698) |
| June 3, 2026 | NCT07622940 | Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622940) |
| June 1, 2026 | NCT07617805 | EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC | Beijing Biotech | Phase 1/2 | Recruiting | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617805) |
| June 1, 2026 | NCT07617753 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617753) |
| May 20, 2026 | NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma | Beijing Biotech | Phase 1/2 | Recruiting | B2 Thymoma, Thymic Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598955) |
| May 15, 2026 | NCT07589543 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589543) |
| May 15, 2026 | NCT07589530 | Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589530) |
| May 15, 2026 | NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589517) |
| April 24, 2026 | NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551362) |
| April 24, 2026 | NCT07551349 | Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551349) |
| April 24, 2026 | NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas, Recurrent Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551336) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| April 13, 2026 | NCT07523542 | SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus | Beijing Biotech | Phase 1/2 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523542) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 6, 2026 | NCT07510828 | PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced or Metastatic Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510828) |
| April 6, 2026 | NCT07510815 | Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma | Beijing Biotech | Phase 1/2 | Recruiting | Malignant Pleural Mesotheliomas | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510815) |
| April 6, 2026 | NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510802) |
| March 30, 2026 | NCT07502287 | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502287) |
| March 30, 2026 | NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500220) |
| March 25, 2026 | NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma | Beijing Biotech | Phase 1 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492628) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 28 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 32 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Recurrence | 8 |
| Neoplasm Metastasis | 6 |
| Ovarian Neoplasms | 4 |
| Glioblastoma | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Carcinoma, Ovarian Epithelial | 3 |
| Glioma | 2 |
| Small Cell Lung Carcinoma | 2 |
| Breast Neoplasms | 2 |
| Fallopian Tube Neoplasms | 2 |
| Stomach Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Prostatic Neoplasms | 2 |
| Colonic Neoplasms | 1 |
| Liver Neoplasms | 1 |
| Simpson-Golabi-Behmel syndrome | 1 |
| Neoplasms | 1 |
| Cholangiocarcinoma | 1 |
| Gallbladder Neoplasms | 1 |
| Biliary Tract Neoplasms | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lupus Nephritis | 1 |
| Burkitt Lymphoma | 1 |
| Lymphoma, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Business consulting firms in the United States](https://specstream.ai/data/businesses/business-consulting-firms/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [Hong Kong style cafes in the United States](https://specstream.ai/data/businesses/hong-kong-style-cafes/united-states)
